4.8 Article

Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1

Journal

NATURE MEDICINE
Volume 15, Issue 8, Pages 955-U161

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/nm.2004

Keywords

-

Funding

  1. US National Institutes of Health (NIH)-National Institute of Allergy Infectious Diseases [R21 AI071806, PO1 AI074415, K01AI062435]
  2. Harvard University Center for AIDS Research
  3. Bill & Melinda Gates Foundation
  4. Doris Duke Charitable Foundation
  5. German Research Society (Deutsche Forschungsgemeinschaft)
  6. National Health and Medical Research Council of Australia [519578]
  7. National Institute of Allergy and Infectious Diseases [AI38855, AI27659, AI38858, AI25879, AI27666]
  8. Agouron/Pfizer, Bristol Myers Squibb and GlaxoSmithKline
  9. US National Cancer Institute (NCI), NIH [HHSN261200800001E]

Ask authors/readers for more resources

Manifestations of viral infections can differ between women and men(1), and marked sex differences have been described in the course of HIV-1 disease. HIV-1-infected women tend to have lower viral loads early in HIV-1 infection but progress faster to AIDS for a given viral load than men(2-7). Here we show substantial sex differences in the response of plasmacytoid dendritic cells (pDCs) to HIV-1. pDCs derived from women produce markedly more interferon-alpha (IFN-alpha) in response to HIV-1-encoded Toll-like receptor 7 (TLR7) ligands than pDCs derived from men, resulting in stronger secondary activation of CD8(+) T cells. In line with these in vitro studies, treatment-naive women chronically infected with HIV-1 had considerably higher levels of CD8(+) T cell activation than men after adjusting for viral load. These data show that sex differences in TLR-mediated activation of pDCs may account for higher immune activation in women compared to men at a given HIV-1 viral load and provide a mechanism by which the same level of viral replication might result in faster HIV-1 disease progression in women compared to men. Modulation of the TLR7 pathway in pDCs may therefore represent a new approach to reduce HIV-1-associated pathology.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available